Menu
Back to Journals » Cancer Management and Research » Volume 15
LncRNA HLA Complex Group 11 Knockdown Alleviates Cisplatin Resistance in Gastric Cancer by Targeting the miR-144-3p/UBE2D1 Axis [Retraction]
Li Y, Wang L, Xu X, Sun H, Wu L. Cancer Manag Res. 2021;13:7543–7557.
We, the Editors and Publisher of Cancer Management and Research, have retracted the following article.
Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images for Figure 7. Specifically,
- The image for Figure 7, MKN45/DDP, sh-HCG11+miR-144-3p inhibitor has overlap with the image for Figure 7, MKN45/DDP, sh-HCG11+pcDNA-UBE2D1.
When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.
We have been informed in our decision-making by our editorial policies and COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
This retraction relates to this paper
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.